Enliven Therapeutics (ELVN) Institutional Ownership $29.41 -0.14 (-0.47%) (As of 01:50 PM ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Enliven Therapeutics (NASDAQ:ELVN)CurrentInstitutional OwnershipPercentage95.08%Number ofInstitutional Buyers(last 12 months)17TotalInstitutional Inflows(last 12 months)$25.71MNumber ofInstitutional Sellers(last 12 months)11TotalInstitutional Outflows(last 12 months)$29.02M Get ELVN Insider Trade Alerts Want to know when executives and insiders are buying or selling Enliven Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ELVN Institutional Buying and Selling by Quarter Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Enliven Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails10/25/2024 China Universal Asset Management Co. Ltd.9,085$232K0.0%+64.4%0.019% 10/10/2024 Exchange Traded Concepts LLC7,483$191K0.0%-60.3%0.016% 10/3/2024 SG Americas Securities LLC10,013$256K0.0%N/A0.021% 8/15/2024The Manufacturers Life Insurance Company13,764$322K0.0%N/A0.029% 8/14/2024Marshall Wace LLP192,100$4.49M0.0%N/A0.408% 8/14/2024Logos Global Management LP595,000$13.91M1.1%-62.2%1.265% Get the Latest News and Ratings for ELVN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/14/2024HighVista Strategies LLC119,789$2.80M1.0%-5.6%0.255% 8/8/2024First Turn Management LLC413,243$9.66M1.6%N/A0.879% 8/8/2024Nicholas Investment Partners LP56,072$1.31M0.1%N/A0.119% 8/8/2024American Century Companies Inc.27,651$646K0.0%+44.7%0.059% 8/6/2024Quest Partners LLC1,592$37K0.0%+87.3%0.003% 8/1/2024Rhumbline Advisers49,627$1.16M0.0%+29.9%0.105% 7/26/2024Bank of New York Mellon Corp114,109$2.67M0.0%+49.2%0.243% 5/16/2024California State Teachers Retirement System19,141$337K0.0%-5.8%0.041% 5/16/2024Janus Henderson Group PLC713,911$12.60M0.0%+74.8%1.519% 5/16/2024Blackstone Inc.25,191$443K0.0%N/A0.054% 5/15/2024Baker BROS. Advisors LP114,833$2.02M0.0%N/A0.244% 5/14/2024EntryPoint Capital LLC9,510$167K0.1%N/A0.020% 5/10/2024Vanguard Group Inc.1,183,266$20.81M0.0%-3.9%2.517% 5/7/2024 SG Americas Securities LLC9,430$166K0.0%-30.2%0.020% 4/29/2024 China Universal Asset Management Co. Ltd.7,952$140K0.0%+67.0%0.017% 2/13/2024Tower Research Capital LLC TRC5,485$76K0.0%-18.8%0.013% 2/6/2024AJOVista LLC2,046$28K0.0%N/A0.005% 2/6/2024Swiss National Bank36,473$505K0.0%-10.3%0.089% 1/24/2024 Mirae Asset Global Investments Co. Ltd.12,305$170K0.0%+9.1%0.030% 1/24/2024 China Universal Asset Management Co. Ltd.4,763$66K0.0%N/A0.012% 1/12/2024 SG Americas Securities LLC13,501$187K0.0%+17.8%0.033% 1/5/2024 Exchange Traded Concepts LLC8,708$121K0.0%+34.0%0.021% 12/6/2023Citigroup Inc.3,347$46K0.0%-69.1%0.008% 11/13/2023FMR LLC3,676,213$50.22M0.0%-8.1%8.923% 11/8/2023Swiss National Bank40,673$556K0.0%-17.3%0.099% 11/7/2023Barclays PLC13,629$186K0.0%-8.1%0.033% 10/23/2023 BML Capital Management LLC50,000$683K0.6%-32.6%0.121% 10/13/2023 SG Americas Securities LLC11,460$157K0.0%N/A0.028% 8/15/2023HighVista Strategies LLC121,073$2.47M1.1%N/A0.294% 8/15/2023Commodore Capital LP2,348,272$47.93M5.4%+35.6%5.707% 8/11/2023VR Adviser LLC2,230,127$45.52M7.3%+0.7%5.423% 8/10/2023Metropolitan Life Insurance Co NY1,279$26K0.0%N/A0.003% 8/4/2023American International Group Inc.11,235$229K0.0%N/A0.027% 8/3/2023Bank of New York Mellon Corp80,924$1.65M0.0%+429.1%0.197% Could TSLA reach $500 a share? Free ebook says it’s possible. (Ad)Even though shares of Tesla are only up 3% this year, one man believes Tesla’s next bull run is just around the corner. In his professional opinion, the share price could reach $500 or more… Now, we understand that may seem far-fetched, but as you’ll see in his new ebook, it’s not as crazy as it may sound. In fact, he argues a Trump presidency could make it happen much faster than you might think. which is why we’re emailing you now… For the time being, he’s giving away his Tesla ebook for free. Inside explains how shares could reach $500 in the near future.To claim your copy, follow this link8/2/2023Bank of Montreal Can191,893$3.95M0.0%N/A0.467% 7/24/2023 BML Capital Management LLC74,232$1.52M1.4%-65.0%0.181% 7/20/2023 Exchange Traded Concepts LLC6,934$142K0.0%N/A0.017% 7/18/2023Denali Advisors LLC9,900$202K0.1%N/A0.024% 6/1/2023Prelude Capital Management LLC34,062$40K0.0%N/A0.519% 5/16/2023Fairmount Funds Management LLC1,924,938$42.16M7.2%N/A29.353% 5/16/2023Boxer Capital LLC710,644$15.56M0.8%N/A10.836% 5/15/2023Commodore Capital LP1,731,365$37.92M5.8%N/A26.401% 5/15/2023Logos Global Management LP401,229$8.79M1.3%N/A6.118% 5/12/2023Mirabella Financial Services LLP11,670$256K0.0%N/A0.178% 5/11/2023FMR LLC3,163,482$69.28M0.0%N/A48.239% 4/20/2023Dorsey Wright & Associates1,237$27K0.0%N/A0.019% (Data available from 1/1/2016 forward) ELVN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ELVN shares? During the previous two years, 38 institutional investors and hedge funds held shares of Enliven Therapeutics. The most heavily invested institutionals were FMR LLC ($50.22M), Commodore Capital LP ($47.93M), VR Adviser LLC ($45.52M), Fairmount Funds Management LLC ($42.16M), Vanguard Group Inc. ($20.81M), Boxer Capital LLC ($15.56M), and Logos Global Management LP ($13.91M).Learn more on ELVN's institutional investors. What percentage of Enliven Therapeutics stock is owned by institutional investors? 95.08% of Enliven Therapeutics stock is owned by institutional investors. Learn more on ELVN's institutional investor holdings. Which institutional investors have been buying Enliven Therapeutics stock? Of the 31 institutional investors that purchased Enliven Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: FMR LLC ($3.16M), Commodore Capital LP ($2.35M), Fairmount Funds Management LLC ($1.92M), Boxer Capital LLC ($710.64K), First Turn Management LLC ($413.24K), Logos Global Management LP ($401.23K), and Janus Henderson Group PLC ($305.40K). How much institutional buying is happening at Enliven Therapeutics? Institutional investors have bought a total of 10,248,214 shares in the last 24 months. This purchase volume represents approximately $221.85M in transactions. Which Enliven Therapeutics major shareholders have been selling company stock? Of the 12 institutional investors that sold Enliven Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Logos Global Management LP ($979.22K), FMR LLC ($325.40K), BML Capital Management LLC ($162.18K), Vanguard Group Inc. ($47.62K), Swiss National Bank ($12.70K), Exchange Traded Concepts LLC ($11.35K), and Citigroup Inc. ($7.48K). How much institutional selling is happening at Enliven Therapeutics? Institutional investors have sold a total of 1,560,738 shares in the last 24 months. This volume of shares sold represents approximately $32.17M in transactions. Related Companies Avadel Pharmaceuticals Institutional Ownership Intellia Therapeutics Institutional Ownership Delcath Systems Institutional Ownership Editas Medicine Institutional Ownership Fulcrum Therapeutics Institutional Ownership bluebird bio Institutional Ownership CRISPR Therapeutics Institutional Ownership Blueprint Medicines Institutional Ownership Avidity Biosciences Institutional Ownership Corcept Therapeutics Institutional Ownership This page (NASDAQ:ELVN) was last updated on 11/7/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredHow high could Bitcoin go?Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELVN Stock Alerts